Reports

1626 Results (Page 1 of 66)

Rare Diseases Markets Research Reports

Rare Diseases

Australia Multiple Myeloma Therapeutics Market Analysis

Australia multiple myeloma therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The increased prevalence of the illness, new technologies, and improved healthcare systems are a few of the elements boosting the revenue of the worldwide multiple myeloma market. Major global players in this market are Teva Pharmaceutical Industries Ltd. Takeda Pharmaceutical Company Limited Genentech Inc. (F. Hoffmann-La Roche Ltd) Novartis AG Celgene Corporation (Bristol Myers Squibb Company) Janssen Pharmaceuticals Inc. (Johnson & Johnson) AbbVie Inc. Ono Pharmaceutical Co. Ltd. Sanofi S.A. Pfizer Inc. Merck & Co. Inc. Eli Lilly and Company Cipla Inc

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jun, 2024 | PRICE: $3999

Rare Diseases

Australia Multiple Myeloma Therapeutics Market Analysis

Australia's multiple myeloma therapeutics market was valued at $100 Mn in 2022 and is estimated to expand at a CAGR of 6% from 2022 to 2030 and will reach $160 Mn in 2030. One of the main reasons propelling the growth of this Market is Increasing healthcare expenditure, Increasing geriatric population. The Market is segmented by type, drug, and distribution channel. Some key players in this Market are CSL, Telix Pharmaceuticals, Mesoblast, Kazia Therapeutics, Immutep, Patrys, Actinogen Medical, Noxopharm, Prima BioMed, Polynovo, and others.

PUBLISHED: Mar, 2023 | FORMAT: PPT | LAST UPDATED: Jun, 2024 | PRICE: $3999

Rare Diseases

Spain Neuroendocrine Tumor Therapeutics Market Analysis

Spain neuroendocrine tumor therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for neuroendocrine tumors is being driven by an increase in the number of cases of these tumors. Major global players in this market are F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Viatris Inc., Thermo Fisher Scientific Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, LUPIN, Exact Sciences Corporation, Pfizer Inc., Ipsen Pharma, Advanced Accelerator Applications (a subsidiary of Novartis AG.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Spain Complex Regional Pain Syndrome (CRPS) Market Analysis

Spain Complex regional pain syndrome (CRPS) Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Complex regional pain syndrome (CRPS) is expanding as a result of rising incidence of complex regional pain syndrome and the growing number of patients suffering from chronic pain and failing back syndrome. Growth in R&D spending by both commercial and public institutions, as well as favourable government legislation and increase in product launches are other factors increasing market growth. Ovid therapeutics, Astra Zeneca, Abbott, GSK, Viatris and Johnson & Johnson Services are the top key market players in Global Complex regional pain syndrome (CRPS) market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

UK Primary Hyperoxaluria (PH) Therapeutics Market Analysis

UK Primary Hyperoxaluria (PH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. One of the key factors propelling the growth of the hyperoxaluria drug market is the rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Therapeutics Market are Allena Pharmaceuticals, Inc., Intellia Therapeutics, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

UK Chronic Inflammatory Demyelinating Polyneuritis Therapeutics Market Analysis

UK Chronic Inflammatory Demyelinating Polyneuritis Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A acquired immune-mediated neuropathy that affects peripheral nerves and nerve roots, chronic inflammatory demyelinating polyneuropathy (CIDP; also known as chronic inflammatory demyelinating polyradiculoneuropathy) is characterised by a progressive or relapsing-remitting course of symmetric weakness of the proximal and distal muscles. Growing government spending and disease awareness have been the market's main drivers for Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics. Bio products laboratory Ltd., Momenta Pharmaceuticals, Grifols, Baxter, Octapharma, Shire, Kedrion SPA, Misubishi Tanabe Pharma Corporation, CSL Behring, and Teijin Pharma Ltd. are global firms in the Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

UK Primary Biliary Cholangitis (PBC) Therapeutics Market Analysis

UK Primary Biliary Cholangitis (PBC) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Due to a variety of critical variables, including growing public awareness of rare diseases, improving healthcare infrastructure, high disposable income, and government backing for cutting-edge autoimmune disease treatments, the market for primary biliary cholangitis treatments is booming.Major global players in Primary Biliary Cholangitis (PBC) Therapeutics Market are Actavis, Inc.; Epic Pharma, LLC; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals; Glenmark Pharmaceuticals, Ltd.; Par Pharmaceutical, Inc.; Intercept Pharmaceuticals, Inc

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

US Mucopolysaccharidosis I (MPS-I) Therapeutics Market Analysis

US Mucopolysaccharidosis I (MPS-I) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Rising consumer awareness, new drug approvals, enticing reimbursement plans, an established healthcare system, and the presence of sizable market competitors all drive the market for treating Mucopolysaccharidosis I. Major global players in this market are Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics, Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

US Myeloproliferative Disorders (MPD) Therapeutics Market Analysis

US Myeloproliferative Disorders (MPD) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for drugs to treat myeloproliferative disorders is expected to expand as a result of the rising prevalence of the different myeloproliferative disorders, the existence of promising pipeline products, regular product approvals, and rising R&D expenditures on the creation of new drugs for the MPD Treatment market. Major global players in this market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd, Bristol Myers Squibb Company, GSK Plc, Bayer AG, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International Gmbh, Sanofi.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market Analysis

Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Increasing funding for medical infrastructure and high rate of multiple sclerosis prevalence (MS) are the major drivers for Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market. Major global players in Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Horizon Therapeutics PLC (Ireland), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), LEO Pharma A/S (Denmark).

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Spain Chronic Inflammatory Demyelinating Polyneuritis Therapeutics Market Analysis

Spain Chronic Inflammatory Demyelinating Polyneuritis Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A acquired immune-mediated neuropathy that affects peripheral nerves and nerve roots, chronic inflammatory demyelinating polyneuropathy (CIDP; also known as chronic inflammatory demyelinating polyradiculoneuropathy) is characterised by a progressive or relapsing-remitting course of symmetric weakness of the proximal and distal muscles. Growing government spending and disease awareness have been the market's main drivers for Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics. Bio products laboratory Ltd., Momenta Pharmaceuticals, Grifols, Baxter, Octapharma, Shire, Kedrion SPA, Misubishi Tanabe Pharma Corporation, CSL Behring, and Teijin Pharma Ltd. are global firms in the Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Spain Charcot-Marie-Tooth Disease (CMT) Therapeutics Market Analysis

Spain Charcot-Marie-Tooth Disease (CMT) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The majority of hereditary peripheral neuropathies are Charcot-Marie-Tooth (CMT) illness, commonly referred to as hereditary motor and sensory neuropathy (HMSN). Genes that support or generate proteins important in the construction and operation of the myelin sheath or the peripheral nerve axon are mutated, leading to CMT. An increase in genetic illnesses will result in more innovations being made in this area, which will enhance market growth because there are many genes that cause these problems. The above-mentioned forecast period will witness the emergence of the market for Charcot Marie-Tooth disease due to multiple prospects that will be heightened by the rising focus on targeted therapies and the favorable government regulations. Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp., Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc. are some of the major players in the Charcot Marie Tooth Disease Market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Hereditary Angioedema Therapeutics Market Analysis

Australia Hereditary Angioedema Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. A uncommon genetic condition known as hereditary angioedema (HAE) is characterised by recurrent episodes of swelling in different body areas. It is brought on by a lack or malfunction of certain proteins involved in controlling the immune response. The regulatory authorities have designated numerous HAE therapies as orphan drugs as a result of this classification, pharmaceutical companies are given some incentives including financial advantages and prolonged exclusivity, which may promote investment in HAE R&D. The increasing prevalence and diagnosis of HAE around the world have been driving the growth of the global market for HAE therapies. This trend offers pharmaceutical businesses the chance to increase their market share, make research and development investments, and introduce novel treatments to various geographic areas. Hereditary angioedema therapies are being developed and produced by a number of international pharmaceutical companies (HAE). Takeda Pharmaceutical Company Limited, Inc., CSL Behring, Pharming Group NV, Ionis Pharmaceuticals, Pharvaris, Dyax Corp., Shire (now a part of Takeda), Attune Pharmaceuticals, Prometic Life Sciences Inc., KalVista Pharmaceuticals, and Biocryst are some of these organisations.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Chronic Inflammatory Demyelinating Polyneuritis Therapeutics Market Analysis

Australia Chronic Inflammatory Demyelinating Polyneuritis Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A acquired immune-mediated neuropathy that affects peripheral nerves and nerve roots, chronic inflammatory demyelinating polyneuropathy (CIDP; also known as chronic inflammatory demyelinating polyradiculoneuropathy) is characterised by a progressive or relapsing-remitting course of symmetric weakness of the proximal and distal muscles. Growing government spending and disease awareness have been the market's main drivers for Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics. Bio products laboratory Ltd., Momenta Pharmaceuticals, Grifols, Baxter, Octapharma, Shire, Kedrion SPA, Misubishi Tanabe Pharma Corporation, CSL Behring, and Teijin Pharma Ltd. are global firms in the Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Primary Biliary Cholangitis (PBC) Therapeutics Market Analysis

Australia Primary Biliary Cholangitis (PBC) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Due to a variety of critical variables, including growing public awareness of rare diseases, improving healthcare infrastructure, high disposable income, and government backing for cutting-edge autoimmune disease treatments, the market for primary biliary cholangitis treatments is booming.Major global players in Primary Biliary Cholangitis (PBC) Therapeutics Market are Actavis, Inc.; Epic Pharma, LLC; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals; Glenmark Pharmaceuticals, Ltd.; Par Pharmaceutical, Inc.; Intercept Pharmaceuticals, Inc

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Angelman Syndrome Therapeutics Market Analysis

Australia During the forecast period of 2023?2030, The Angelman Syndrome Therapeutics Market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. An uncommon inherited neuro-developmental condition called Angelman Syndrome is marked by a severe developmental delay, sleep issues, jerky movements, and a lot of laughter. As the illness is more common, there are more government measures to manage it. This has also helped with research and development for condition treatment. These factors collectively represent the Angelman Syndrome Therapeutics Market's driving forces. Boston Children's Hospital, the Angelman Syndrome Foundation, Rady Children's Hospital in San Diego, General Hospital Corporation, Cincinnati Children's Hospital Medical Center, and others are major competitors in the market for treating Angelman syndrome.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia ATTR (Transthyretin Amyloidosis) Therapeutics Market Analysis

Australia ATTR (Transthyretin Amyloidosis) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. An rare and progressive condition known as ATTR (Transthyretin Amyloidosis) is characterised by the buildup of aberrant proteins in the body, including misTTR. The market for treatments for transthyretin amyloidosis is primarily driven by the expansion of the population and the availability of favourable reimbursement programmes. The market is predicted to increase as a result of strategic actions done by major players such raising knowledge of the target conditions like ATTR and the long-term advantages of treatments that are currently accessible. The market for treating transthyretin amyloidosis is currently constrained by a number of factors, including low awareness of the condition in developing nations, misdiagnosis of the condition, high costs of disease diagnosis and treatment, the lack of adequate clinical trials, and the absence of effective medications. Pfizer Inc., Johnson & Johnson Services, Inc., Ionis Pharmaceuticals, Alnylam Pharmaceuticals, BridgeBio Pharma, Bristol-Myers Squibb Company, Acrotech Biopharma, AstraZeneca, Astellas Pharma, Inc., Prothena, SOM Biotech, and numerous others are global competitors in the ATTR (Transthyretin Amyloidosis) market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia MPS-III (Sanfilippo Syndrome) Drugs Market Analysis

Australia MPS-III (Sanfilippo Syndrome) drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for MPS-III (Sanfilippo Syndrome) drugs is growing rapidly as a result of increase in research and development activities, patient support and advocacy programmes, launch of new emerging therapies, increase in healthcare spending globally. Phoenix Nest Inc, Allievex Corp, Amicus Therapeutics Inc, ArmaGen Inc, Esteve Pharmaceuticals SA, JCR Pharmaceuticals Co Ltd, M6P Therapeutics, Orchard Therapeutics Plc, Seelos Therapeutics, Inc., and BioStrategies LC are top key players operating in global MPS-III (Sanfilippo Syndrome) drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Mucopolysaccharidosis I (MPS-I) Drugs Market Analysis

Australia Mucopolysaccharidosis I (MPS-I) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Rising consumer awareness, new drug approvals, enticing reimbursement plans, an established healthcare system, and the presence of sizable market competitors all drive the market for treating Mucopolysaccharidosis I. Major global players in Mucopolysaccharidosis I (MPS-I) Drugs Market are Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Drugs, Abeona Drugs, Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Drugs, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Charcot-Marie-Tooth Disease (CMT) Therapeutics Market Analysis

Australia Charcot-Marie-Tooth Disease (CMT) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The majority of hereditary peripheral neuropathies are Charcot-Marie-Tooth (CMT) illness, commonly referred to as hereditary motor and sensory neuropathy (HMSN). Genes that support or generate proteins important in the construction and operation of the myelin sheath or the peripheral nerve axon are mutated, leading to CMT. An increase in genetic illnesses will result in more innovations being made in this area, which will enhance market growth because there are many genes that cause these problems. The above-mentioned forecast period will witness the emergence of the market for Charcot Marie-Tooth disease due to multiple prospects that will be heightened by the rising focus on targeted therapies and the favorable government regulations. Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp., Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc. are some of the major players in the Charcot Marie Tooth Disease Market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Herpes Simplex Virus Therapeutics Market Analysis

Australia Herpes Simplex Virus Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Herpes simplex virus (HSV) is a common viral infection that can cause a range of diseases in humans. High Prevalence of HSV Infections, Increasing Awareness and Diagnosis, Continued research and development efforts, Technological advancements and Increasing healthcare expenditure, particularly in developed countries, provides a supportive environment for the growth of the HSV Therapeutics market. Social stigma surrounding herpes, Drug-resistant HSV strains provided by limited treatment options are restraining factors in herpes simplex therapeutics market. GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Novartis AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd. Are global key players in herpes simplex therapeutics market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Adrenoleukodystrophy (ALD) Therapeutics Market Analysis

Australia Adrenoleukodystrophy (ALD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Drivers of acromegaly market are increasing cases of the disorder which in turn increased awareness and government focus motivated financial support to R&D. Poxel SA, Bluebird Bio Inc.,Viking Technologies, Minoryx Therapeutics sl., Apteeus SAS, Ashvattha Therapeutics LLC, NeuroVia Company, Autobahn Therapeutics Inc., Aldagen Inc., Celularity Inc., Imstem Biotechnology Inc., MedDay SA, and Orpheris Inc. are major competitors in the Australia Adrenoleukodystrophy (ALD) drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Batten's Disease (CLN-2) Therapeutics Market Analysis

Australia Batten?s Disease (CLN-2) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Neuronal Ceroid Lipofuscinosis (NCL), often known as Batten disease, is a rare and severe autosomal recessive neurodegenerative lysosomal storage condition brought on by cellular buildup of aberrant auto-fluorescent lipoproteins (lipofuscin). Seizures and a progressive loss of movement, verbal, visual, and cognitive abilities are features of this neurodegenerative condition that primarily affects the nerve system. Research advancements in nanotechnology could result in the creation of fresh therapies that would benefit persons who suffer from this ailment. Additionally, it is a paediatric brain condition that is extremely rare yet progresses quickly. As a result, Batten's Disease may be exacerbated by the predicted rising prevalence of disease. Therapeutics market (CLN-2). The market for Batten's Disease (CLN-2) Therapeutics is constrained by a lack of treatment and symptoms that are challenging to identify. Regenxbio, Polaryx Therapeutics and Abeona Therapeutics are some of the key players in the market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Primary Hyperoxaluria (PH) Drugs Market Analysis

Australia Primary Hyperoxaluria (PH) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Unmet Medical Need, Increasing Awareness and Diagnosis, Advancements in Research and Development, Growing Investment and Pipeline Development, Collaboration and Patient Advocacy,rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Drugs Market are Allena Pharmaceuticals, Inc., Intellia Drugs, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Sanfilippo Syndrome (MPS-III) Therapeutics Market Analysis

Australia Sanfilippo Syndrome (MPS-III) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Sanfilippo Syndrome (MPS-III) Therapeutics is growing rapidly as a result of increase in research and development activities, patient support and advocacy programmes, launch of new emerging therapies, increase in healthcare spending globally. Phoenix Nest Inc, Allievex Corp, Amicus Therapeutics Inc, ArmaGen Inc, Esteve Pharmaceuticals SA, JCR Pharmaceuticals Co Ltd, M6P Therapeutics, Orchard Therapeutics Plc, Seelos Therapeutics, Inc., and BioStrategies LC are top key players operating in global Sanfilippo Syndrome (MPS-III) Therapeutics market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

subscribe to our newsletter
up